<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Metachromatic leukodystrophy
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Metachromatic leukodystrophy
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Metachromatic leukodystrophy
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Joshua L Bonkowsky, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Marc C Patterson, MD, FRACP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Helen V Firth, DM, FRCP, FMedSci
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John F Dashe, MD, PhD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Feb 15, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Metachromatic leukodystrophy (sulfatide lipidosis; MLD) is a rare autosomal recessive lysosomal storage disease that causes progressive demyelination of the central and peripheral nervous system.
        </p>
        <p>
         This topic will review the clinical manifestations, diagnosis, and treatment of metachromatic leukodystrophy. Other lysosomal storage disorders and leukodystrophies are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6200.html" rel="external">
          "Clinical features, evaluation, and diagnosis of X-linked adrenoleukodystrophy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1695.html" rel="external">
          "Alexander disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1702.html" rel="external">
          "Aspartoacylase deficiency (Canavan disease)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1692.html" rel="external">
          "Cerebrotendinous xanthomatosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6194.html" rel="external">
          "Fabry disease: Neurologic manifestations"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6188.html" rel="external">
          "Krabbe disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2931.html" rel="external">
          "Mucopolysaccharidoses: Clinical features and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6196.html" rel="external">
          "Overview of Niemann-Pick disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1693.html" rel="external">
          "Pelizaeus-Merzbacher disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1699.html" rel="external">
          "Sjögren-Larsson syndrome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1701.html" rel="external">
          "Vanishing white matter disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H977153559">
         <span class="h1">
          ETIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         MLD is caused by deficient activity of the lysosomal enzyme arylsulfatase A (ARSA) as a result of, in almost all cases, pathogenic variants in the arylsulfatase A gene (
         <em>
          ARSA
         </em>
         ). Of note, there is a variant form with different clinical characteristics caused by a deficiency of sphingolipid activator protein SAP-B (saposin B), which normally stimulates the degradation of sulfatides by ARSA [
         <a href="#rid1">
          1
         </a>
         ]. This form is caused by pathogenic variants in the prosaposin gene (
         <em>
          PSAP
         </em>
         ).
        </p>
        <p>
         ARSA is responsible for the desulfation of cerebroside sulfate, a major glycolipid of myelin. As a result, decreased ARSA activity leads to the accumulation of cerebroside sulfate in the central nervous system, peripheral nerves, kidneys, and other visceral organs. The accumulation of cerebroside sulfate destroys oligodendroglial and Schwann cells, causing central and peripheral demyelination. Electron microscopy shows thickened lines in the myelin whorls and lamellar inclusions of sulfatides in the Schwann cells [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h2">
          Genetics
         </span>
         <span class="headingEndMark">
          —
         </span>
         Over 60 pathogenic
         <em>
          ARSA
         </em>
         variants have been described in MLD. Two alleles, A and I, together account for approximately 50 percent of cases [
         <a href="#rid3">
          3,4
         </a>
         ]. These alleles contribute to the different clinical expressions of the disease [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Homozygosity for the I allele is associated with very low or undetectable residual ARSA activity and late infantile onset; compound heterozygotes (with the other allele unknown) also appear to have a late infantile onset.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Homozygosity for the A allele is associated with low but detectable residual ARSA activity and the juvenile or adult onset forms; compound heterozygotes have later onset of disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The presence of both alleles is associated with juvenile onset.
        </p>
        <p>
        </p>
        <p>
         There is evidence for a correlation between genotype and phenotype in late-onset MLD, a category that includes late juvenile and adult onset [
         <a href="#rid5">
          5
         </a>
         ]. Patients who are homozygous for the
         <em>
          ARSA
         </em>
         P426L variant generally present with progressive gait disturbance (spastic paraparesis or cerebellar ataxia), while mental involvement becomes evident later. In contrast, compound heterozygotes for
         <em>
          ARSA
         </em>
         I179S variant present with schizophrenia-like behavioral abnormalities, social dysfunction, and mental decline, but motor deficits are scarce. (See
         <a class="local">
          'Juvenile and adult onset'
         </a>
         below.)
        </p>
        <p>
         Some normal individuals have low ARSA enzyme activity approximating those of patients with MLD. This nonpathogenic reduction in ARSA activity is caused by homozygosity for the
         <em>
          ARSA
         </em>
         pseudodeficiency allele. This allele contains two sequence alterations, a polyadenylation defect, and an amino acid substitution. The combined effect of these changes is to reduce ARSA enzyme activity to approximately 8 percent of normal [
         <a href="#rid6">
          6
         </a>
         ]. The frequency of the allele is about 10 percent in most populations, resulting in a 1 percent frequency of the pseudodeficiency phenotype [
         <a href="#rid6">
          6,7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H988968878">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prevalence of MLD ranges from 1:40,000 to 1:100,000 in northern European and North American populations [
         <a href="#rid8">
          8,9
         </a>
         ]. However, a higher prevalence has been found in certain groups including Habbanite Jews in Israel, Arabs living in Israel, and Navajo Indians in the United States [
         <a href="#rid10">
          10-12
         </a>
         ].
        </p>
        <p>
         In a retrospective review of 122 children with an inherited leukodystrophy from a regional center in Utah, MLD was the etiology in 8 percent, making it the most common diagnosis, similar in frequency to Pelizaeus-Merzbacher disease (7 percent), and higher in frequency than mitochondrial diseases (5 percent) or adrenoleukodystrophy (4 percent) [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Three major subtypes of MLD are primarily distinguished by the age at disease onset [
         <a href="#rid3">
          3
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Late infantile onset (age 6 months to 2 years)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Juvenile onset (age 3 to &lt;16 years)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adult onset (age ≥16)
        </p>
        <p>
        </p>
        <p>
         Peripheral neuropathy occurs in all forms and may be a presenting feature, particularly in the late infantile form  (
         <a class="graphic graphic_table graphicRef56567" href="/z/d/graphic/56567.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid14">
          14-16
         </a>
         ]. Gallbladder involvement is common with manifestations that include hyperplastic polyps and a probable increased risk of gallbladder carcinoma [
         <a href="#rid17">
          17-21
         </a>
         ].
        </p>
        <p>
         Earlier age at onset and the presence of motor symptoms at onset regardless of age have been associated with rapid disease progression, while onset with cognitive symptoms only has been associated with milder disease progression [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Late infantile onset
         </span>
         <span class="headingEndMark">
          —
         </span>
         The late infantile form of MLD typically appears at six months to two years of age, though onset up to age four is considered late infantile by some investigators [
         <a href="#rid23">
          23
         </a>
         ]. Infants and toddlers may present with developmental delay or regression of motor skills due to the peripheral nerve involvement even before any evidence of brain magnetic resonance imaging (MRI) changes. Other early signs can include gait difficulties, seizures, ataxia, hypotonia, extensor plantar responses, and optic atrophy [
         <a href="#rid23">
          23,24
         </a>
         ]. Deep tendon reflexes are sometimes reduced or absent, reflecting the peripheral neuropathy. The prognosis is worse than later onset forms of MLD; progression to death typically occurs within five to six years.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Juvenile and adult onset
         </span>
         <span class="headingEndMark">
          —
         </span>
         The juvenile onset form of MLD is heterogeneous in presentation. Some children present between four and six years of age (early juvenile) with, intellectual impairment, behavioral difficulties, gait disturbance, ataxia, upper motor neuron signs, and a peripheral neuropathy [
         <a href="#rid23">
          23,25
         </a>
         ]. Seizures may occur, and progression to death occurs within six years of onset. Another group of children present between 6 and 16 years of age (late juvenile) with behavioral changes and intellectual impairment and, in many cases, seizures. Progression is slower, and these children may survive until early adulthood.
        </p>
        <p>
         Adult onset MLD (age 17 years or older) is usually heralded by dementia and behavioral difficulties, and a substantial minority present with neuropathy, psychosis, schizophrenia, or seizures [
         <a href="#rid23">
          23
         </a>
         ]. Optic atrophy has also been reported [
         <a href="#rid26">
          26
         </a>
         ]. A late onset or adult onset phenotype limited to psychiatric disease with minimal or no motor findings is well-described but often remains undiagnosed for many years; The course is static or very slowly progressive [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1048028759">
         <span class="h2">
          Investigations
         </span>
         <span class="headingEndMark">
          —
         </span>
         In late-onset MLD, nerve conduction studies show marked slowing. Sensory potentials are affected earlier and more severely than are motor responses [
         <a href="#rid28">
          28,29
         </a>
         ]. There is segmental demyelination with metachromatic material in Schwann cells and macrophages on peripheral nerve biopsy [
         <a href="#rid30">
          30,31
         </a>
         ].
        </p>
        <p>
         Brain MRI reveals symmetric white matter lesions with a periventricular and/or frontal predominance. The subcortical U-fibers are usually spared. A tigroid (striped) pattern of white matter T2-weighted hyperintensities is seen in 70 percent of cases; cortical atrophy is seen with disease progression  (
         <a class="graphic graphic_algorithm graphicRef65871" href="/z/d/graphic/65871.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid32">
          32,33
         </a>
         ]. A retrospective study reported that levels of N-acetylaspartate (NAA) measured by magnetic resonance spectroscopy may be useful in therapeutic trials as a biomarker of MLD disease progression [
         <a href="#rid34">
          34
         </a>
         ], but the utility of NAA levels in clinical practice is not established.
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical picture combined with a typical brain MRI should suggest the diagnosis of MLD. However, the diagnosis can be challenging, particularly for the late infantile form, as the normal MRI, together with hyporeflexia and developmental delay, is relatively nonspecific. Reduced nerve conduction velocity and elevated cerebrospinal fluid protein concentrations may also be helpful to arrive at the diagnosis.
        </p>
        <p>
         The diagnosis of MLD is established by identification of pathogenic
         <em>
          ARSA
         </em>
         variant, together with deficient arylsulfatase A (ARSA) enzyme activity in leukocytes. In patients with MLD, ARSA activity levels typically range from undetectable to less than 10 percent of normal values. However, diagnosis based only on the activity of ARSA is complicated by the existence of ARSA pseudodeficiency, which is present in approximately one percent of the general population. As a result, screening for the presence of the pseudodeficiency alleles is important when low but not absent levels are detected in prenatal testing or screening of asymptomatic relatives [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         Availability of newborn screening for MLD is limited and is not yet recommended in the United States by the federal Recommended Uniform Screening Panel [
         <a href="#rid35">
          35
         </a>
         ]. MLD newborn screening, based on detection of elevated blood sulfatide levels, is occurring in Germany and in New York [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are no fully curative therapies for MLD, but early MLD is a treatable disease. Allogeneic hematopoietic cell transplantation (HSCT) is the first-line treatment option offered for eligible patients. Ex vivo HSCT gene therapy has also been associated with benefit and is approved for treatment in the European Union.
        </p>
        <p class="headingAnchor" id="H2120792624">
         <span class="h2">
          Hematopoietic stem cell transplantation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Allogeneic HSCT is the standard of care for eligible patients with no or early MLD disease involvement.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mechanism
         </strong>
         – HSCT introduces healthy donor cells that migrate into the brain of recipients, engraft, and express arylsulfatase A (ARSA), the enzyme that is deficient in MLD.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Benefit
         </strong>
         – HSCT appears to treat central nervous system (CNS) manifestations of MLD but not peripheral neuropathy [
         <a href="#rid37">
          37-40
         </a>
         ]. Long-term follow-up suggests continued progression of the peripheral neuropathy [
         <a href="#rid40">
          40
         </a>
         ]. The type of symptoms at presentation correlate with response to therapy [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Donor selection
         </strong>
         – Although not available for many patients with MLD, the preferred HSCT donor is a noncarrier, human leukocyte antigen-matched sibling [
         <a href="#rid41">
          41
         </a>
         ]. The next best option is umbilical cord blood, which offers many practical advantages over unrelated donor bone marrow or peripheral blood stem cell donors, including an expanded donor pool, ease of procurement, and decreased rates of graft-versus-host disease (GVHD). If the preferred options are not available, unrelated bone marrow donors are preferred to peripheral blood stem cell donors, since the latter has been associated with a higher incidence of GVHD in pediatric patients [
         <a href="#rid42">
          42,43
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3537.html" rel="external">
          "Hematopoietic cell transplantation (HCT): Sources of hematopoietic stem/progenitor cells"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patient selection
         </strong>
         – Data suggest that early transplantation (best presymptomatically) is necessary for positive outcomes [
         <a href="#rid44">
          44
         </a>
         ]. Patients with juvenile or adult onset MLD who have mild, early symptoms are appropriate candidates for HSCT [
         <a href="#rid43">
          43
         </a>
         ]. Older patients with advanced disease are unlikely to benefit. (See
         <a class="local">
          'Juvenile and adult onset'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with late-infantile onset who are symptomatic are also unlikely to benefit from HSCT since they have inexorable progression of symptoms leading to death within a few years. (See
         <a class="local">
          'Late infantile onset'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Procedure
         </strong>
         – HSCT for MLD generally is performed with myeloablative conditioning regimens (eg,
         <a class="drug drug_general" data-topicid="9173" href="/z/d/drug information/9173.html" rel="external">
          busulfan
         </a>
         and
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         , with or without antithymocyte globulin) to provide adequate immunosuppression and prevent graft rejection; this results in pancytopenia, which is reversed by infusion of the hematopoietic stem cells (HSCs). Seizure prophylaxis, typically with
         <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">
          levetiracetam
         </a>
         , is necessary during busulfan treatment. (See
         <a class="medical medical_review" href="/z/d/html/3557.html" rel="external">
          "Preparative regimens for hematopoietic cell transplantation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Prophylaxis of GVHD is important. Approaches vary; one common regimen involves treatment with a calcineurin inhibitor plus
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil. (See
         <a class="medical medical_review" href="/z/d/html/3542.html" rel="external">
          "Prevention of graft-versus-host disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Complications
         </strong>
         – Transplantation-related mortality is high, ranging from 17 to 43 percent in two reports of HSCT for juvenile MLD [
         <a href="#rid39">
          39,40
         </a>
         ]. HSCT is also associated with numerous complications that can affect multiple organ systems. These are reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/15803.html" rel="external">
          "Early complications of hematopoietic cell transplantation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1403.html" rel="external">
          "Overview of infections following hematopoietic cell transplantation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3549.html" rel="external">
          "Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3543.html" rel="external">
          "Treatment of acute graft-versus-host disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/122403.html" rel="external">
          "Survival, quality of life, and late complications after hematopoietic cell transplantation in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3548.html" rel="external">
          "Clinical manifestations and diagnosis of chronic graft-versus-host disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H912203071">
         <span class="h2">
          Ex vivo gene therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ex vivo gene therapy with HSCT is a promising treatment option for MLD [
         <a href="#rid45">
          45-47
         </a>
         ] and has been approved for clinical use in the European Union [
         <a href="#rid48">
          48
         </a>
         ]. Use of ex vivo gene therapy may be considered based upon availability, individual patient factors, and shared decision-making with patients, families, and caregivers. However, ex vivo gene therapy has not been compared with standard HSCT, short- and long-term complications remain a concern, cost is greater, and consensus recommendations for treatment with HSCT or ex vivo HSCT gene therapy have not been established.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mechanism
         </strong>
         – A lentiviral vector is used to transfer a functional
         <em>
          ARSA
         </em>
         gene into autologous HSCs [
         <a href="#rid49">
          49
         </a>
         ]. The gene-corrected HSCs (atidarsagene autotemcel [arsa-cel]) are then transfused back into patients. This leads to stable engraftment of the transduced HSCs and high levels of ARSA enzyme activity.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Benefit
         </strong>
         – Limited data suggest prevention of symptom onset or a halt in disease progression [
         <a href="#rid46">
          46,50
         </a>
         ]. In a nonrandomized, open-label study of 29 children with presymptomatic or early-symptomatic late infantile or early juvenile MLD who were treated with arsa-cel, two patients died due to MLD progression and one died due to an ischemic stroke [
         <a href="#rid50">
          50
         </a>
         ]. The 26 surviving patients showed sustained engraftment of genetically modified HSCs. At two years after treatment, ARSA enzyme activity was increased above baseline, scores for gross motor function were increased compared with an untreated natural-history control group, and most treated children had either normal development or stabilization of motor skills, including maintaining the ability to walk. In addition, most treated children had normal cognitive development and absence or delay of brain white matter involvement and brain atrophy; patients with late infantile onset showed improvement of peripheral nerve conduction velocity. The benefits of arsa-cel treatment were most apparent in patients who were presymptomatic when treatment started.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Complications
         </strong>
         – Ex vivo gene therapy with HSCT appears to avert the risk of GVHD; however, patients still require the transplant process, and long-term safety and risk for lentiviral insertional mutagenesis continue to be studied. Although generally well-tolerated, adverse events associated with arsa-cel therapy in reported studies were mainly related to myeloablative conditioning with
         <a class="drug drug_general" data-topicid="9173" href="/z/d/drug information/9173.html" rel="external">
          busulfan
         </a>
         used for HSCT, most commonly febrile neutropenia and stomatitis; and less commonly veno-occlusive disease and thrombotic microangiopathy [
         <a href="#rid46">
          46,50
         </a>
         ]. A minority of patients developed anti-ARSA antibodies, which resolved either spontaneously or after B cell depletion therapy using
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         .
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H993534045">
         <span class="h2">
          Other therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other experimental options for MLD are being explored, including direct (in vivo) viral gene therapy [
         <a href="#rid51">
          51,52
         </a>
         ] and enzyme replacement therapy [
         <a href="#rid53">
          53,54
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H977153517">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Metachromatic leukodystrophy (MLD) is an autosomal recessive lysosomal storage disease caused by pathogenic variants in the arylsulfatase A gene (
         <em>
          ARSA
         </em>
         ). In a few patients, a variant form of MLD is caused by pathogenic variants in the prosaposin gene (
         <em>
          PSAP
         </em>
         ). (See
         <a class="local">
          'Etiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The prevalence of MLD ranges from 1:40,000 to 1:100,000 in northern European and North American populations. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Three major subtypes of MLD are primarily distinguished by the age at disease onset and include late infantile, juvenile, and adult forms. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The late infantile form of MLD presents from age six months to two years; early signs include regression of motor skills, gait difficulty, ataxia, hypotonia, extensor plantar responses, optic atrophy, and peripheral neuropathy. (See
         <a class="local">
          'Late infantile onset'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The juvenile form of MLD presents between 3 and 16 years of age with gait disturbance, intellectual impairment, ataxia, upper motor neuron signs, and a peripheral neuropathy. Seizures may occur.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Adult onset MLD (age 17 or older) is usually heralded by dementia and behavioral difficulties. (See
         <a class="local">
          'Juvenile and adult onset'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The diagnosis of MLD is established by demonstrating genetic pathogenic variants in
         <em>
          ARSA
         </em>
         , together with deficient arylsulfatase A (ARSA) enzyme activity in leukocytes. Diagnosis based only on the level of ARSA enzyme activity is complicated by the existence of ARSA pseudodeficiency. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There is no fully curative treatment for MLD, but allogeneic hematopoietic cell transplantation (HSCT) appears to halt or prevent disease progression in pre- or early symptomatic patients. HSCT combined with gene therapy is approved in Europe. Other investigational therapies include viral gene therapy or enzyme therapy. (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H142975942">
         <span class="h1">
          ACKNOWLEDGMENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Robert Cruse, DO, and Raphael Schiffmann, MD, MHSc, FAAN, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Wrobe D, Henseler M, Huettler S, et al. A non-glycosylated and functionally deficient mutant (N215H) of the sphingolipid activator protein B (SAP-B) in a novel case of metachromatic leukodystrophy (MLD). J Inherit Metab Dis 2000; 23:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomas PK, King RH, Kocen RS, Brett EM. Comparative ultrastructural observations on peripheral nerve abnormalities in the late infantile, juvenile and late onset forms of metachromatic leukodystrophy. Acta Neuropathol 1977; 39:237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Polten A, Fluharty AL, Fluharty CB, et al. Molecular basis of different forms of metachromatic leukodystrophy. N Engl J Med 1991; 324:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berger J, Löschl B, Bernheimer H, et al. Occurrence, distribution, and phenotype of arylsulfatase A mutations in patients with metachromatic leukodystrophy. Am J Med Genet 1997; 69:335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rauschka H, Colsch B, Baumann N, et al. Late-onset metachromatic leukodystrophy: genotype strongly influences phenotype. Neurology 2006; 67:859.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harvey JS, Carey WF, Morris CP. Importance of the glycosylation and polyadenylation variants in metachromatic leukodystrophy pseudodeficiency phenotype. Hum Mol Genet 1998; 7:1215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barth ML, Ward C, Harris A, et al. Frequency of arylsulphatase A pseudodeficiency associated mutations in a healthy population. J Med Genet 1994; 31:667.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gustavson KH, Hagberg B. The incidence and genetics of metachromatic leucodystrophy in northern Sweden. Acta Paediatr Scand 1971; 60:585.
          </a>
         </li>
         <li class="breakAll">
          Von Figura K, Gieselmann V, Jacken J. Metachromatic leukodystrophy. In: The Metabolic and Molecular Bases of Inherited Disease, 8th ed, Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw-Hill, New York 2001. p.3695.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zlotogora J, Bach G, Barak Y, Elian E. Metachromatic leukodystrophy in the habbanite Jews: high frequency in a genetic isolate and screening for heterozygotes. Am J Hum Genet 1980; 32:663.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heinisch U, Zlotogora J, Kafert S, Gieselmann V. Multiple mutations are responsible for the high frequency of metachromatic leukodystrophy in a small geographic area. Am J Hum Genet 1995; 56:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holve S, Hu D, McCandless SE. Metachromatic leukodystrophy in the Navajo: fallout of the American-Indian wars of the nineteenth century. Am J Med Genet 2001; 101:203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonkowsky JL, Nelson C, Kingston JL, et al. The burden of inherited leukodystrophies in children. Neurology 2010; 75:718.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malone MJ, Stoffyn P. Peripheral nerve glycolipids in metachromatic leukodystrophy. Neurology 1967; 17:1033.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fressinaud C, Vallat JM, Masson M, et al. Adult-onset metachromatic leukodystrophy presenting as isolated peripheral neuropathy. Neurology 1992; 42:1396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cameron CL, Kang PB, Burns TM, et al. Multifocal slowing of nerve conduction in metachromatic leukodystrophy. Muscle Nerve 2004; 29:531.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ries M, Deeg KH. Polyposis of the gallbladder associated with metachromatic leukodystrophy. Eur J Pediatr 1993; 152:450.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simanovsky N, Ackerman Z, Kiderman A, Fields S. Unusual gallbladder findings in two brothers with metachromatic leukodystrophy. Pediatr Radiol 1998; 28:706.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cappell MS, Marks M, Kirschenbaum H. Massive hemobilia and acalculous cholecystitis due to benign gallbladder polyp. Dig Dis Sci 1993; 38:1156.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garavelli L, Rosato S, Mele A, et al. Massive hemobilia and papillomatosis of the gallbladder in metachromatic leukodystrophy: a life-threatening condition. Neuropediatrics 2009; 40:284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Rappard DF, Bugiani M, Boelens JJ, et al. Gallbladder and the risk of polyps and carcinoma in metachromatic leukodystrophy. Neurology 2016; 87:103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kehrer C, Elgün S, Raabe C, et al. Association of Age at Onset and First Symptoms With Disease Progression in Patients With Metachromatic Leukodystrophy. Neurology 2021; 96:e255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahmood A, Berry J, Wenger DA, et al. Metachromatic leukodystrophy: a case of triplets with the late infantile variant and a systematic review of the literature. J Child Neurol 2010; 25:572.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zafeiriou DI, Kontopoulos EE, Michelakakis HM, et al. Neurophysiology and MRI in late-infantile metachromatic leukodystrophy. Pediatr Neurol 1999; 21:843.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MacFaul R, Cavanagh N, Lake BD, et al. Metachromatic leucodystrophy: review of 38 cases. Arch Dis Child 1982; 57:168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quigley HA, Green WR. Clinical and ultrastructural ocular histopathologic studies of adult-onset metachromatic leukodystrophy. Am J Ophthalmol 1976; 82:472.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Rappard DF, de Vries ALC, Oostrom KJ, et al. Slowly Progressive Psychiatric Symptoms: Think Metachromatic Leukodystrophy. J Am Acad Child Adolesc Psychiatry 2018; 57:74.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takakura H, Nakano C, Kasagi S, et al. Multimodality evoked potentials in progression of metachromatic leukodystrophy. Brain Dev 1985; 7:424.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wulff CH, Trojaborg W. Adult metachromatic leukodystrophy: neurophysiologic findings. Neurology 1985; 35:1776.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dayan AD. Peripheral neuropathy of metachromatic leucodystrophy: observations on segmental demyelination and remyelination and the intracellular distribution of sulphatide. J Neurol Neurosurg Psychiatry 1967; 30:311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luijten JA, Straks W, Blikkendaal-Lieftinck LF, et al. Metachromatic leukodystrophy: a comparative study of the ultrastructural findings in the peripheral nervous system of three cases, one of the late infantile, one of the juvenile and one of the adult form of the disease. Neuropadiatrie 1978; 9:338.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schiffmann R, van der Knaap MS. Invited article: an MRI-based approach to the diagnosis of white matter disorders. Neurology 2009; 72:750.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Groeschel S, Kehrer C, Engel C, et al. Metachromatic leukodystrophy: natural course of cerebral MRI changes in relation to clinical course. J Inherit Metab Dis 2011; 34:1095.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           i Dali C, Hanson LG, Barton NW, et al. Brain N-acetylaspartate levels correlate with motor function in metachromatic leukodystrophy. Neurology 2010; 75:1896.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hong X, Daiker J, Sadilek M, et al. Toward newborn screening of metachromatic leukodystrophy: results from analysis of over 27,000 newborn dried blood spots. Genet Med 2021; 23:555.
          </a>
         </li>
         <li class="breakAll">
          https://mldnewbornscreening.org/ (Accessed on October 13, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solders M, Martin DA, Andersson C, et al. Hematopoietic SCT: a useful treatment for late metachromatic leukodystrophy. Bone Marrow Transplant 2014; 49:1046.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Hosson LD, van de Warrenburg BP, Preijers FW, et al. Adult metachromatic leukodystrophy treated by allo-SCT and a review of the literature. Bone Marrow Transplant 2011; 46:1071.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boucher AA, Miller W, Shanley R, et al. Long-term outcomes after allogeneic hematopoietic stem cell transplantation for metachromatic leukodystrophy: the largest single-institution cohort report. Orphanet J Rare Dis 2015; 10:94.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Groeschel S, Kühl JS, Bley AE, et al. Long-term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Juvenile Metachromatic Leukodystrophy Compared With Nontransplanted Control Patients. JAMA Neurol 2016; 73:1133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Page KM, Stenger EO, Connelly JA, et al. Hematopoietic Stem Cell Transplantation to Treat Leukodystrophies: Clinical Practice Guidelines from the Hunter's Hope Leukodystrophy Care Network. Biol Blood Marrow Transplant 2019; 25:e363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eapen M, Horowitz MM, Klein JP, et al. Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. J Clin Oncol 2004; 22:4872.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keesler DA, St Martin A, Bonfim C, et al. Bone Marrow versus Peripheral Blood from Unrelated Donors for Children and Adolescents with Acute Leukemia. Biol Blood Marrow Transplant 2018; 24:2487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van den Broek BTA, Page K, Paviglianiti A, et al. Early and late outcomes after cord blood transplantation for pediatric patients with inherited leukodystrophies. Blood Adv 2018; 2:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Batzios SP, Zafeiriou DI. Developing treatment options for metachromatic leukodystrophy. Mol Genet Metab 2012; 105:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sessa M, Lorioli L, Fumagalli F, et al. Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1/2 trial. Lancet 2016; 388:476.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jensen TL, Gøtzsche CR, Woldbye DPD. Current and Future Prospects for Gene Therapy for Rare Genetic Diseases Affecting the Brain and Spinal Cord. Front Mol Neurosci 2021; 14:695937.
          </a>
         </li>
         <li class="breakAll">
          www.ema.europa.eu/en/medicines/human/EPAR/libmeldy (Accessed on October 14, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biffi A, Montini E, Lorioli L, et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 2013; 341:1233158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fumagalli F, Calbi V, Natali Sora MG, et al. Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1/2 trial and expanded access. Lancet 2022; 399:372.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Audouard E, Oger V, Meha B, et al. Complete Correction of Brain and Spinal Cord Pathology in Metachromatic Leukodystrophy Mice. Front Mol Neurosci 2021; 14:677895.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenberg JB, Chen A, De BP, et al. Safety of Direct Intraparenchymal AAVrh.10-Mediated Central Nervous System Gene Therapy for Metachromatic Leukodystrophy. Hum Gene Ther 2021; 32:563.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Í Dali C, Groeschel S, Moldovan M, et al. Intravenous arylsulfatase A in metachromatic leukodystrophy: a phase 1/2 study. Ann Clin Transl Neurol 2021; 8:66.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Í Dali C, Sevin C, Krägeloh-Mann I, et al. Safety of intrathecal delivery of recombinant human arylsulfatase A in children with metachromatic leukodystrophy: Results from a phase 1/2 clinical trial. Mol Genet Metab 2020; 131:235.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6195 Version 24.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10682309" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : A non-glycosylated and functionally deficient mutant (N215H) of the sphingolipid activator protein B (SAP-B) in a novel case of metachromatic leukodystrophy (MLD).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/199031" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Comparative ultrastructural observations on peripheral nerve abnormalities in the late infantile, juvenile and late onset forms of metachromatic leukodystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1670590" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Molecular basis of different forms of metachromatic leukodystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9096767" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Occurrence, distribution, and phenotype of arylsulfatase A mutations in patients with metachromatic leukodystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16966551" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Late-onset metachromatic leukodystrophy: genotype strongly influences phenotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9668161" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Importance of the glycosylation and polyadenylation variants in metachromatic leukodystrophy pseudodeficiency phenotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7815433" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Frequency of arylsulphatase A pseudodeficiency associated mutations in a healthy population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5110535" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : The incidence and genetics of metachromatic leucodystrophy in northern Sweden.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5110535" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : The incidence and genetics of metachromatic leucodystrophy in northern Sweden.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6107044" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Metachromatic leukodystrophy in the habbanite Jews: high frequency in a genetic isolate and screening for heterozygotes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7825603" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Multiple mutations are responsible for the high frequency of metachromatic leukodystrophy in a small geographic area.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11424134" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Metachromatic leukodystrophy in the Navajo: fallout of the American-Indian wars of the nineteenth century.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20660364" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : The burden of inherited leukodystrophies in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4167615" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Peripheral nerve glycolipids in metachromatic leukodystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1320219" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Adult-onset metachromatic leukodystrophy presenting as isolated peripheral neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15052618" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Multifocal slowing of nerve conduction in metachromatic leukodystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8319717" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Polyposis of the gallbladder associated with metachromatic leukodystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9732500" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Unusual gallbladder findings in two brothers with metachromatic leukodystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8508713" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Massive hemobilia and acalculous cholecystitis due to benign gallbladder polyp.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20446223" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Massive hemobilia and papillomatosis of the gallbladder in metachromatic leukodystrophy: a life-threatening condition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27261095" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Gallbladder and the risk of polyps and carcinoma in metachromatic leukodystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33046606" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Association of Age at Onset and First Symptoms With Disease Progression in Patients With Metachromatic Leukodystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20038527" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Metachromatic leukodystrophy: a case of triplets with the late infantile variant and a systematic review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10593679" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Neurophysiology and MRI in late-infantile metachromatic leukodystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7073297" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Metachromatic leucodystrophy: review of 38 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/961798" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Clinical and ultrastructural ocular histopathologic studies of adult-onset metachromatic leukodystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29413149" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Slowly Progressive Psychiatric Symptoms: Think Metachromatic Leukodystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4061780" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Multimodality evoked potentials in progression of metachromatic leukodystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4069371" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Adult metachromatic leukodystrophy: neurophysiologic findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4168052" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Peripheral neuropathy of metachromatic leucodystrophy: observations on segmental demyelination and remyelination and the intracellular distribution of sulphatide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/218147" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Metachromatic leukodystrophy: a comparative study of the ultrastructural findings in the peripheral nervous system of three cases, one of the late infantile, one of the juvenile and one of the adult form of the disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19237705" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Invited article: an MRI-based approach to the diagnosis of white matter disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21698385" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Metachromatic leukodystrophy: natural course of cerebral MRI changes in relation to clinical course.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21098404" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Brain N-acetylaspartate levels correlate with motor function in metachromatic leukodystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33214709" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Toward newborn screening of metachromatic leukodystrophy: results from analysis of over 27,000 newborn dried blood spots.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33214709" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Toward newborn screening of metachromatic leukodystrophy: results from analysis of over 27,000 newborn dried blood spots.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24797185" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Hematopoietic SCT: a useful treatment for late metachromatic leukodystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21042305" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Adult metachromatic leukodystrophy treated by allo-SCT and a review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26245762" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Long-term outcomes after allogeneic hematopoietic stem cell transplantation for metachromatic leukodystrophy: the largest single-institution cohort report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27400410" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Long-term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Juvenile Metachromatic Leukodystrophy Compared With Nontransplanted Control Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31499213" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Hematopoietic Stem Cell Transplantation to Treat Leukodystrophies: Clinical Practice Guidelines from the Hunter's Hope Leukodystrophy Care Network.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15520055" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30142417" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Bone Marrow versus Peripheral Blood from Unrelated Donors for Children and Adolescents with Acute Leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29344584" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Early and late outcomes after cord blood transplantation for pediatric patients with inherited leukodystrophies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22078456" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Developing treatment options for metachromatic leukodystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27289174" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1/2 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34690692" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Current and Future Prospects for Gene Therapy for Rare Genetic Diseases Affecting the Brain and Spinal Cord.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34690692" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Current and Future Prospects for Gene Therapy for Rare Genetic Diseases Affecting the Brain and Spinal Cord.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23845948" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35065785" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1/2 trial and expanded access.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34093126" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Complete Correction of Brain and Spinal Cord Pathology in Metachromatic Leukodystrophy Mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33380277" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Safety of Direct Intraparenchymal AAVrh.10-Mediated Central Nervous System Gene Therapy for Metachromatic Leukodystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33332761" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Intravenous arylsulfatase A in metachromatic leukodystrophy: a phase 1/2 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32792226" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Safety of intrathecal delivery of recombinant human arylsulfatase A in children with metachromatic leukodystrophy: Results from a phase 1/2 clinical trial.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
